Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in early 2022, SynBioVen is a UK-based venture capital firm dedicated to supporting synthetic biology startups. The firm focuses on early-stage investments, particularly in proof of concept, pre-seed, and seed funding, with a portfolio of seven companies. Their mission centers on the belief that synthetic biology will significantly impact the next industrial revolution and aid in achieving a net-zero economy.
SynBioVen invests in early-stage synthetic biology ventures, providing funding and access to expertise in research, business development, and financing. They typically engage with startups at the proof of concept, pre-seed, and seed stages. Their R&D Hub in West London, in collaboration with SynbiCITE and the London Biofoundry, enhances their support for portfolio companies.
Notable companies in SynBioVen's portfolio include Colorifix, which has developed an environmentally friendly dyeing process; Scindo, a platform converting plastic waste into valuable molecules; and Eden Bio, utilizing machine learning for genetic engineering. Other portfolio companies include Multus, Resurrect bio, Chain Biotech, and Valink Therapeutics.
To pitch SynBioVen, submit your proposal through their website's contact form.
Yes, SynBioVen often leads funding rounds for the startups they invest in, particularly at the pre-seed and seed stages.
SynBioVen is open to follow-on investments, especially for companies that demonstrate significant progress and alignment with their mission in synthetic biology.
Specific details about the size of SynBioVen's current fund are not publicly available.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.